Edgewise Therapeutics
EWTX38.4406.52% ( -2.680 )
Edgewise Therapeutics (EWTX)
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead prod...
- Open
- 41.110
- High
- 41.110
- Low
- 38.440
- Prev. Close
- 41.120
- Volume
- 644.44K
- Turnover
- 25.26M
- Avg Price
- 39.204
- Bid/Ask Ratio
- --
- Amplitude
- 6.49%
- 52wk High
- 48.400
- Volume Ratio
- 0.81
- Turnover Ratio
- 0.96%
Edgewise Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 17, 2026Price forecast
$49.9229.87%
Forecast & RatingBuy
12analysts
- Strong buy66.67%
- Buy16.67%
- Hold16.67%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 16 at 07:02 AM
Edgewise Therapeutics files amended 8-K with unaudited pro forma financials for Servier asset sale
- Tip Ranks · Jul 13 at 12:28 PM
Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier
- StockTitan · Jul 12 at 11:30 PM
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline | EWTX Stock News
- Tip Ranks · Jul 2 at 09:05 PM
Top Edgewise Therapeutics Executive Makes Major Move With Insider Stock Sale
- PUBT · Jul 2 at 04:21 PM
Edgewise Therapeutics CSO Alan J. Russell sells 200,000 common shares worth $7.88 million
- PUBT · Jul 1 at 07:05 AM
Edgewise Therapeutics grants inducement stock options for 16,500 shares at $40.63 each
